Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase

A compound having the formula:

• or a pharmaceutically acceptable salt thereof, wherein:
• each of X1 and X2 is, independently, N or CH;
• R1 is —C(O)H, —C(O)R1a, —C(O)N(R1a)(R1b), or a 5- or 6-membered heteroaryl ring having 1-3 heteroatoms selected from N, O, or S and optionally substituted with 1, 2 or 3 JR2 groups;
• R1a is C1-6 aliphatic, C3-6 cycloaliphatic, azetidinyl, pyrrolidinyl, or piperidinyl, wherein R1a is optionally substituted with 1, 2, 3, or 4, occurrences of JR;
• R1b is hydrogen, C1-4 aliphatic, or R1a and R1b, together with the nitrogen to which they are attached, form a 4-6 membered heterocyclic ring, wherein said heterocyclic ring of R1a and R1b optionally comprises one additional heteroatom selected from nitrogen and oxygen, and wherein said heterocyclic ring of R1a and R1b is optionally substituted with 1 or 2 JR2 groups;
• each JR is independently fluoro, oxo, —C(O)JR1, —C(O)N(JR1)2, —C(O)O(JR1), —N(JR1)C(O)JR1, —OJR1, —SJR1, phenyl or a 5-6 membered heteroaryl or heterocyclyl having up to 2 atoms selected from nitrogen, oxygen, or sulfur, wherein said phenyl, heteroaryl, or heterocyclyl or JR is optionally substituted with 1 or 2 JR2 groups;
• each JR1 is independently selected from hydrogen, C1-4aliphatic, C3-6cycloaliphatic, phenyl, benzyl, heterocyclyl, or heteroaryl, wherein said heterocyclyl of JR1 is a 5- or 6-membered ring having 1 or 2 atoms selected from N, or O, said heteroaryl of R2 is a 5- or 6-membered monocyclic ring or a 9- or 10-membered fused bicyclic ring system having 1, 2, or 3 atoms selected from N, O, or S, and each of said aliphatic, cycloaliphatic, phenyl, benzyl, heterocyclyl, or heteroaryl of JR1 is optionally substituted with up to three JR2 groups;
• each JR2 is selected from chloro, fluoro, oxo, C1-2alkyl, C1-2alkyl substituted with 1-3 fluorine atoms, C3-6cycloalkyl, —OH, —OC1-2alkyl, —OC1-2alkyl substituted with 1-3 fluorine atoms, —C(O)C1-2alkyl, or —SC1-2alkyl;
• R2 is hydrogen, fluoro, chloro, C1-6aliphatic, —OC1-6aliphatic, C3-6cycloaliphatic, —OC3-6cycloaliphatic, cyano, —NH2, —NHC1-6aliphatic, —NHC3-6cycloaliphatic, —NHS(O)2C1-6aliphatic, —NHS(O)2C3-6cycloaliphatic, —NHS(O)2phenyl, —NHS(O)2benzyl, —NHS(O)2heteroaryl, —S(O)2C1-6aliphatic, —S(O)2C3-6cycloaliphatic, —S(O)2phenyl, —S(O)2benzyl, —S(O)2heteroaryl, —S(O)2NHC1-6aliphatic, —S(O)2NHC3-6cycloaliphatic, —S(O)2NHphenyl, —S(O)2NHbenzyl, or —S(O)2NHheteroaryl, wherein said heteroaryl of R2 is a 5- or 6-membered ring having 1, 2, or 3 atoms selected from N, O, or S, and wherein said aliphatic, cycloaliphatic, phenyl, benzyl, or heteroaryl of R2 is optionally substituted with 1, 2, or 3 JR2 groups;
• and
• R3 is hydrogen, fluoro, chloro, C1-3aliphatic, —OC1-3aliphatic, NH2, or NHC1-3aliphatic, wherein said aliphatic of R3 is optionally substituted with up to 3 occurrences of fluoro.